Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.56 per share and revenue of $16.42 million for the quarter.
Fennec Pharmaceuticals Trading Up 1.0 %
NASDAQ FENC opened at $6.88 on Friday. The company has a market cap of $189.63 million, a PE ratio of -68.79 and a beta of 0.34. Fennec Pharmaceuticals has a 12 month low of $3.96 and a 12 month high of $11.49. The stock has a 50 day moving average of $6.39 and a 200-day moving average of $5.61.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Friday, December 20th. Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Tuesday, December 17th.
Insider Buying and Selling at Fennec Pharmaceuticals
In other news, Director Rosty Raykov sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $6.66, for a total value of $66,600.00. Following the completion of the sale, the director now owns 76,294 shares of the company’s stock, valued at approximately $508,118.04. The trade was a 11.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 31,186 shares of company stock valued at $203,389 in the last quarter. 10.98% of the stock is currently owned by insiders.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Recommended Stories
- Five stocks we like better than Fennec Pharmaceuticals
- How Investors Can Find the Best Cheap Dividend Stocks
- Is Myers Industries Poised for a Breakout?
- The How And Why of Investing in Oil Stocks
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- What is a Death Cross in Stocks?
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
